Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
- 30 June 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (6), 739-744
- https://doi.org/10.1016/0277-5379(91)90178-g
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Quantitative Determination of Factors Contributing to Doxorubicin Resistance in Multidrug-Resistant CellsJNCI Journal of the National Cancer Institute, 1989
- Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.Journal of Clinical Oncology, 1989
- Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery diseaseThe American Journal of Cardiology, 1989
- Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cellsThe FASEB Journal, 1988
- Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell linesCancer Chemotherapy and Pharmacology, 1987
- Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: Role of protein bindingCancer Letters, 1987
- Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- Verapamil Reversal of Clinical Doxorubicin Resistance in Human Cancer A Wilshire Oncology Medical Group Pilot Phase I-II StudyAmerican Journal of Clinical Oncology, 1986
- Pharmacokinetics and metabolism of bepridilThe American Journal of Cardiology, 1985
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell LinesScience, 1983